Gyógyszerészet 2020. október

Egy szakirodalmi áttekintés alapján a kávéfogyasztás széles körben elfogadott a világ minden táján. A napi kávézás – függetlenül az elkészítési módszertől és a koffeintartalomtól – nem növeli a szív- és érrendszeri betegségek és más krónikus betegségek többségének kockázatát, éppen ellenkezőleg, napi 3-5 csésze kávé, komponenseinek köszönhetően, összefüggésbe hozható az össz-mortalitás csökkenésével. Így a kávézás akár az egészséges életmód része is lehet.

Azonban a kávé mértéktelen fogyasztása és/vagy egyes kávé-gyógyszer kölcsönhatások káros hatásokat eredményezhetnek, ezért a biztonságos kávéfogyasztás érdekében mindenkinek tisztában kell lennie azzal, hogy az anyagcsere és a kávéérzékenység inter-individuális különbségeket mutat.

IRODALOM

1. Derossi A, Ricci I et al. How grinding level and brewing method (espresso, american, turkish) could affect the antioxidant activity and bioactive compounds in a coffee cup. J Sci Food Agric. 2017;98:3198-207. – 2. Gunter MJ, Murphy N et al. Coffee drinking and mortality in ten European countries – the EPIC study. Ann Intern Med. 2017;167: 236-47. – 3. Angeloni G, Guerrini L et al. What kind of coffee do you drink? An investigation on effects of eight different methods. Food Res Intern. 2019;116:1327-35. – 4. Bell LN, Wetzel CR, Grand AN. Caffeine content in coffee as influenced by grinding and brewing conditions. Food Res Int. 1996;29:785-9. – 5. Cappelleti S, Piacentino D et al. Caffein-related deaths: manner of deaths and categories at risk. Nutrients. 2018;10(5):611. – 6. Lisko JG, Lee GE et al. Caffeine concentrations in coffee, tea, chocolate, and energy drink flavored e-liquids. Nicotine Tob Res. 2017;19:484-92. – 7. Naveed M, Hejazi V et al. Chlorogenic acid (CGA): a pharmacological review and call for further research. Biomed Pharmacother. 2018;97:67-74. – 8. Dhanya R, Arya AD et al. Quercetin, a lead compound against type 2 diabetes ameliorates glucose uptake via AMPK pathway in skeletal muscle cell line. Front Pharmacol. 2017;8:336. – 9. Poole R, Kennedy OJ et al. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. Brit Med J. 2017;359:j5024. – 10. Li Q, Liu Y et al. Caffeinated and decaffeinated coffee consumption and risk of all-cause mortality: a dose-response meta-analysis of cohort studies. J Hum Nutr Diet. 2019;32:279-87. – 11. Loftfield E, Cornelis MC et al. Association of coffee drinking with mortality by genetic variation in caffeine metabolism. JAMA Intern Med. 2018;178:1086-97. – 12. Freedman ND, Park Y et al. Association of coffee drinking with total and cause-specific mortality. N Eng J Med. 2011;366:1891-904. – 13. Farag NH, Vincent AS et al. Caffein tolerance is incomplete: persistent blood pressure responses in the ambulatory settings. Am J Hypertens. 2005;18:714-19. – 14. Juhanfar S, Jaafar SH. Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcomes (review). Cochrane Database Syst Rev. 2015 Jun 9;(6):CD006965. – 15. Urgert R, Essed N et al. Separate effects of the coffee diterpenes cafestol and kahweolon serum lipids and liver aminotransferases. Am J. Clin Nutr.  1997;65:519-24. – 16. Hao W-R, Sung L-C et al. Cafestol inhibits cyclic-stain-induced interleukin-8, intracelular adhesion molecule-1, and monocyte chemoattractant protein-1 in vascular endothelial cells. Oxid Med Cell Longev. 2018:7861518. – 17. Ren Y, Wang C et al. Cafestol and kahweol: a review of their bioactivities and pharmacological properties. Int J Molec Sci. 2019;20:4238. – 18. Belayneh A, Molla F. The effect of coffee on pharmacokinetic properties of drugs: a review. Biomed Res Internat. 2020:7909703. – 19. Culm-Merdek KE, von Moltke LL et al. Fluvoxamine impairs single-dose caffeine cearance without affecting caffeine pharmacodynamics. Br J Pharmacol. 2005;60:486-93. – 20. Raaska K, Raitasuo V et al. Effect of caffeine-containing versus decaffeinated coffee on serun clozapine concentrations in hospitalized patients. Basic Clin Pharmacol Toxicol. 2003;94:13-8. – 21. Myslobodsky M. The paradox of caffein-zolpidem interaction: a network analysis. Curr Drug Targets. 2009;10:1009-20. – 22. Cappelletti S, Daria P et al. Caffeine: cognitive and phyasical performance enhancer or psychoactive drug? Curr Neuropharmacol 2015;13:71-88. – 23. Dresser GK, Urquhart BL et al. Coffee inhibition of CYP3A4 in vitro was not translated to a grapefruit-like pharmacokinetic interaction clinically. Pharma Res Prosp. 2017;5(5):e00346. – 24. Treur JL, Taylor AE et al. Observational association between smoking and caffein consumption in two European cohorts. Addiction. 2019;111:1059-68. – 25. Tan DD, Natesen S et al. Effects of common CYP1A2 genotypes and other key factors on individual variation in the caffeine metabolic ratio: an exploratory analysis. Clin Transl Sci. 2019;12:39-46. – 26. Coe S, Ryan L. Impact of  polyphenol-rich sources on acute postprandial glycaemia:a systematic review. J Nutr Sci. 2016;5(e24):1-11. – 27. Salomone F, Galvano F, Li Volti G. Molecular basis underlying the hepatoprotective effects of coffee. Nutrients. 2017;9(1):85. – 28. Xiao J, Huang W-Het al. Quercetin significantly inhibits the metabolism of caffein, a substrate of cytochrom P-4501A2 unrelated to CYP 1A2*1C(-2964G<A) and 1F (734C>A) gene polymorphisms.  Biomed Res Interat. 2014:405071. – 29. Iwamoto H, Izumi K et al. Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells. Prostate. 2019;79:468-79. – 30. Fukuyama Y, Hidaka K et al. Novel xantine oxydase (XO) inhibitory phenylindanes produced by thermal reaction of caffeic acid. Biosci Biotechnol Biochem. 2019;82:1825-28. – 31. Skelin M, Lucijanic T et al. Factors affecting gastrointestinal absorption of levothyroxine: a review. Clin Ther. 2017;39:378-403. – 32. Ulvik A, Vollset SE et al. Coffee consumption and circulating B-vitamins in healthy middle-aged men and women. Clin Chem. 2008;54:1489-96.

Télessy I.: Thoughts about our daily coffee…and the same of patients’

Based on a literature review, coffee consumption is widely accepted over the world. Daily drinking of coffee – independently of the brewing method and the caffeine content – does not increase the risk of cardiovascular diseases and majority of other chronic illnesses, on the contrary, due to coffee components, daily 3-5 cups of coffee has been associated with reduced all-cause mortality. Thus, it may be part of a healthy lifestyle. However, consumption of too much coffee and/or unfortunate coffee-drug interaction can result in adverse effects therefore one should be aware of the existence of inter-individual differences in metabolism and sensitivity to coffee in order to keep the safe side.

Az innovatív gyógyszerhordozó rendszerek kialakítására alkalmas technikák közül a különböző módszerekkel előállított nano- és mikroszálas szerkezetek gyógyszerészeti és orvosbiológiai felhasználása a gyakorlati és ipari megvalósíthatóság küszöbén áll. A szálas rendszerek különleges tulajdonságai nagy lehetőségeket biztosítanak a gyógyszerfejlesztés során. Ezekre alapozva olyan formulációk alakíthatók ki, melyek – megnövelve a rosszul oldható hatóanyagok oldhatóságát és így biohasznosíthatóságát – csökkenthetik az alkalmazandó dózist vagy repozicio-nál-hatnak már létező kémiai entitásokat. Kihasználva szövetregenerációt serkentő hatásukat, a szálas rendszerek felszívódó kötszerként és helyi készítményekként is alkal-maz-hatók a sebgyógyulás segítésére. Az ígéretesnek tűnő felhasználási lehetőségek ellenére számos gyakorlati kérdés merül fel, amelyeket szükséges időben megválaszolni ahhoz, hogy meghatározhassuk a technológia potenciális ipari alkalmazhatóságát. Közleményünk a szálas rendszerek gyógyszertechnológiai alkalmazhatóságának lehetőségeit és limitációit teszi kritikus vizsgálat tárgyává, ugyanakkor ismerteti orvostechnikai eszközként való felhasználásukat is.

Irodalom

1. Ostwald W. Die Welt der Vernachlassigten Dimensionen: eine Einführung in die moderne Kolloidchemie mit besonderer Berücksichtigung ihrer Anwendungen. 1. kiadás. Dresden und Leipzig: Theodor Steinkoppf; 1914. – 2. Feynman R. There’s plenty of room at the bottom: An invitation to enter a new field of physics. Eng Sci. 1960;23:22-36. – 3. Brus L. Electronic wave functions in semiconductor clusters – experiment and theory, J Phys Chem. 1986;90:2355-560. – 4. Horváth A, Beck A et al. Effect of different treatments of Aerosil silica-supported Pd nanopartciles produced by ‘controlled colloidal synthesis’. Solid State Ionics. 2001;141-142:147-52. – 5. Papp S, Szél J et al. Synthesis of polymer stabilized rhodium nanoparticles in the interlayer space of layer silicates. Chem Mater. 2004;16:1674-85. – 6. Gupta V, Kothari V. Manufactured fibre technology. Dordrecht: Springer Science & Business Media; 2012. 14-30. p. – 7. Cooley JF. Apparatus for electrically dispersing fluids. US692631A. 1902.02.04. – 8. Tucker N, Stanger J et al. The history of the science and technology of electrospinning from 1600 to 1995. J Eng Fiber Fabr. 2012;7:63-73. – 9. Varabhas JS, Chase GG et al. Electrospun nanofibers from a porous hollow tube. Polymer. 2008;49:4226-9. – 10. Beachley V, Wen X. Effect of electrospinning parameters on the nanofiber diameter and length. Mater Sci Eng. 2009;29:663-8. – 11. Greiner A, Wendorff JH. Electrospinning: a fascinating method for the preparation of ultrathin fibers. Angew Chem Int Edit. 2007;46:5670-703. – 12. Megelski S, Stephens JS et al. Micro-and nanostructured surface morphology on electrospun polymer fibers. Macromolecules. 2002;35:8456-66. – 13. Reneker DH, Chun I. Nanometre diameter fibres of polymer, produced by electrospinning. Nanotechnology. 1996;7:216-23. – 14. Zhou FL, Gong RH. Manufacturing technologies of polymeric nanofibres and nanofibre yarns. Polym Int. 2008;57:837-45. – 15. Dévay A, Antal I. A gyógyszeres terápia biofarmáciai alapjai. Budapest: Medicina; 2009. 183-207. p. – 16. Siepmann J, Siepmann F. Mathematical modeling of drug dissolution. Int J Pharm. 2013;453:12-24. – 17. Liu L, Che B. Preparation of monolithic osmotic pump system by coating the indented core tablet. Eur J Pharm and Biopharm. 2006;64:180-4. – 18. Park K, Mrsny RJ. Controlled Drug Delivery: Present and Future. In: American Chemical Society Symposium Series, Controlled Drug Delivery. 752. kötet Washington: American Chemical Society; 2000. 2-12. p. – 19. Mansour HM, Sohn M et al. Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects. Int J Mol Sci. 2010;11:3298-322. – 20. Amidon GL, Lennernäs H et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-20. – 21. Lipinski CA, Lombardo F et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliver Rev. 1997;23:3-25. – 22. Keserü GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov. 2009;8:203-12. – 23. Hann MM. Molecular obesity, potency and other addictions in drug discovery. Med Chem Comm. 2011;2:349-55. – 24. Brough C, Williams RO. Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery. Int J Pharm. 2013;453:157-66. – 25. Singhal D, Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv Drug Deliv Rev. 2004;56:335-47. – 26. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29:278-87. – 27. Kawabata Y, Wada K et al. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2011;420:1-10. – 28. Krishnaiah YS. Pharmaceutical technologies for enhancing oral bioavailability of poorly soluble drugs. J Bioequiv Availab. 2010;2:28-36. – 29. Nagy ZK, Balogh A et al. High speed electrospinning for scaled-up production of amorphous solid dispersion of itraconazole. Int J Pharm. 2015;480:137-42. – 30. Lakshman JP, Cao Y et al. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug. Mol Pharmaceut. 2008;5:994-1002. – 31. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci. 1971;60:1281-302. – 32. Van den Mooter G. The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate. Drug Discov Today Technol. 2012;9:79-85. – 33. Sebe I. Nano- és mikroszálas gyógyszerhordozó rendszerek formulálása és a szálas struktúra topikális, terápiás alkalmazhatóságának in vitro és in vivo vizsgálata [PhD tézis]. [Budapest]: Semmelweis Egyetem; 2018. – 34. Murugan R, Ramakrishna S. Design strategies of tissue engineering scaffolds with controlled fiber orientation. Tissue Eng. 2007;13:1845-66. – 35. Freed LE, Vunjak-Novakovic G et al. Biodegradable polymer scaffolds for tissue engineering. Nat Biotechnol. 1994;12:689-93. – 36. Pham QP, Sharma U et al. Electrospinning of polymeric nanofibers for tissue engineering applications: a review. Tissue Eng. 2006;12:1197-211. – 37. Zhong S, Teo WE et al. An aligned nanofibrous collagen scaffold by electrospinning and its effects on in vitro fibroblast culture. J Biomed Mater Res A. 2006;79:456-63. – 38. Chandrasekaran AR, Venugopal J et al. Fabrication of a nanofibrous scaffold with improved bioactivity for culture of human dermal fibroblasts for skin regeneration. Biomed Mater. 2011;6:015001. – 39. Lee YJ, Lee JH et al. Electrospun fibers immobilized with bone forming peptide-1 derived from BMP7 for guided bone regeneration. Biomaterials. 2013;34:5059-69. – 40. Choi JS, Leong KW et al. In vivo wound healing of diabetic ulcers using electrospun nanofibers immobilized with human epidermal growth factor (EGF). Biomaterials. 2008;29:587-96. – 41. Ko S, Jang J. Protein immobilization on aminated poly(glycidyl methacrylate) nanofibers as polymeric carriers. Biomacromolecules. 2007;8:1400-3. – 42. Boland ED, Matthews JA et al. Electrospinning collagen and elastin: Preliminary vascular tissue engineering. Front Biosci. 2014;9:1422-32. – 43. Li M, Mondrinos MJ et al. Electrospun protein fibers as matrices for tissue engineering. Biomaterials. 2005;26:5999-6008. – 44. Matthews JA, Wnek GE et al. Electrospinning of collagen nanofibers. Biomacromolecules. 2002;3:232-8. – 45. Ji W, Yang F et al. Fibrous scaffolds loaded with protein prepared by blend or coaxial electrospinning. Acta Biomater. 2010;6:4199-207. – 46. Sahoo S, Ang LT et al. Growth factor delivery through electrospun nanofibers in scaffolds for tissue engineering applications. J Biomed Mater Res A. 2010;93:1539-50. – 47. Zahedi P, Rezaeian I et al. A review on wound dressings with an emphasis on electrospun nanofibrous polymeric bandages. Polym Adv Technol. 2010;21:77-95. – 48. Chong EJ, Phan TT et al. Evaluation of electrospun PCL/gelatin nanofibrous scaffold for wound healing and layered dermal reconstitution. Acta Biomater. 2007;3:321-30. – 49. Smith DJ, Reneker DH, McManus AT, Schreuder-Gibson HL, Mello C, Sennett MS. Electrospun fibers and an apparatus therefor. US6753454B1. 2004.06.22. – 50. Wu H, Fan J et al. Electrospinning of small diameter 3-D nanofibrous tubular scaffolds with controllable nanofiber orientations for vascular grafts. J Mater Sci – Mater M. 2010;21:3207-15. – 51. Xie J, Li X et al. Putting electrospun nanofibers to work for biomedical research. Macromol Rapid Comm. 2008;29:1775-92. – 52. Ratcliffe A. Tissue engineering of vascular grafts. Matrix Biol. 2000;19:353-7. – 53. Liu S, Dong C et al. Bilayered vascular grafts based on silk proteins. Acta Biomater. 2013;9:8991-9003. – 54. Lee SJ, Yoo JJ et al. In vitro evaluation of electrospun nanofiber scaffolds for vascular graft application. J Biomed Mater Res A. 2007;83:999-1008. – 55. Hall JW, Eller Z, Kellar RS, Simmons RL, Mower W, Radford RJ. Rotational spun material covered medical appliances and methods of manufacture. US20140074225A1. 2013.11. – 56. Stamberg BE. Process of making a medical balloon. US8992817B2. 2015.03.31. – 57. Ko EK, Jeong SI et al. In vitro osteogenic differentiation of human mesenchymal stem cells and in vivo bone formation in composite nanofiber meshes. Tissue Eng A. 2008;14:2105-19. – 58. Kijeńska E, Prabhakaran MP et al. Interaction of Schwann cells with laminin encapsulated PLCL core-shell nanofibers for nerve tissue engineering. Eur Polym J. 2014;50:30-8. – 59. Gupta D, Venugopal J et al. Aligned and random nanofibrous substrate for the in vitro culture of Schwann cells for neural tissue engineering. Acta Biomater. 2009;5:2560-9. – 60. Katti DS, Robinson KW et al. Bioresorbable nanofiber-based systems for wound healing and drug delivery: Optimization of fabrication parameters. J Biomed Mater Res B: Appl Biomater. 2004;70:286-96. – 61. Stadelmann WK, Digenis AG et al. Impediments to wound healing. Am J Surg. 1998;176:39S-47S. – 62. Field CK, Kerstein MD. Overview of wound healing in a moist environment. Am J Surg. 1994;167:S2-S6. – 63. Wongkaev N. Nanofiber-integrated miniaturized systems: an intelligent platform for cancer diagnosis. Anal Bioanal Chem. 2019;411:4251–64. – 64. Xiao J, Shen M et al. Design of functional electrospun nanofibers for cancer cell capture applications. J Mater Chem B. 2018;6:1420-32.

Sebe I., Zelkó R.: Positioning of electrostatic fiber formation in pharmaceutical, biomedical and medical applications: part I – pharmaceutical feasibility aspects

Among the techniques suitable for the formulation of innovative drug delivery systems, the pharmaceutical and biomedical applications of nano- and microfiber structures produced by different spinning methods are on the verge of practical and industrial feasibility. The properties of fibrous systems provide great potential in development. Based on these, it is also possible to develop formulations, which can be part of real pharmaceutical preparations in the future by increasing the solubility and the consequent bioavailability of poorly soluble active ingredients, thus reducing the appropriate dose or repositioning existing chemical entities. By the use of the tissue regeneration-promoting effect of the fibrous structure, it can also be applied in the form of absorbable dressings and topical preparations to aid wound healing. Despite the promising applications, many practical questions arise that need to be answered on time to determine the potential industrial feasibility of the technology. The following study attempts to provide a critical assessment of the possibilities and limitations of the pharmaceutical technology applicability of fibrous systems, as well as to highlight their specific areas of medical devices.